Insights

Can Snap Revenue Growth Beat Q1 Expectations Amid Redesign Criticism?

Wedbush’s Michael Pachter on one hand likes Snap’s revenue prospects for the first quarter against the Street; yet on the other hand, the analyst stays sidelined on dipping trends.

Square (SQ): Here’s What to Expect from a Weebly Takeover; Nomura Shares Two Cents

Nomura’s Dan Dolev takes Square’s just-revealed M&A buzz in bullish favor, spotlighting encouraging revenue potential ahead.

Maxim Sees 382% Upside for Helios and Matheson (HMNY) Stock; Here’s Why

Maxim’s Nehal Chokshi sees a trajectory heading towards a sustainable business model for HMNY.

Advanced Micro Devices (AMD): Get Ready for Some Upside Come 1Q18 Earnings Show, Predicts Rosenblatt

Rosenblatts’ Hans Mosesmann is especially upbeat on AMD’s new Ryzen models, in what he calls a record for the chip giant’s “most prolific new product ramp” to date.

Biotech Talk: Cowen Shares Thoughts on Dynavax (DVAX) Following Favorable Data in Advanced Head and Neck Cancer

Cowen’s Phil Nadeau sings the praises of this “undervalued” biotech stock, encouraged to see DVAX’s cancer drug SD-101 revealed well tolerated results in a mid-stage trial.

Oppenheimer Cuts Sales Expectations for Synergy Pharmaceuticals (SGYP) Approaching 1Q18 Print; But Better Sales Growth Ahead?

Oppenheimer’s Christopher Liu thinks the Street is too confident on SGYP ahead of its first earnings show of the year- opting for now to stick to the sidelines.

Here’s Why Analysts Like These Two Chip Giants: Micron Technology (MU), Intel Corporation (INTC)

One top analyst sings Micron’s praises despite concerns of DRAM pricing weakness; another analyst lifts expectations on standout Intel fundamentals.

Alibaba Group (BABA): Jason Helfstein Highlights Strength in New Retail and Lazada Commerce Growth Prospects

Oppenheimer’s Jason Helfstein has taken a close, confident look into BABA’s new retail and international pieces of the puzzle.

GBH Says to Buy Amazon.com, Inc. (AMZN) Stock Despite Presidential ‘Bullseye’ on Its Back and Facebook, Inc. (FB) Amid ‘Darkest Chapter in 14 Years’

Though FANG name fears are running rampant through the Street, Daniel Ives remains a bull when it comes to bets on AMZN and FB.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts